A century-old debate on protein aggregation and neurodegeneration enters the clinic

Nature

Volumn 443, Issue 7113, 2006, Pages 774-779

  Lansbury, Peter T ^a,b   Lashuel, Hilal A ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Link Medicine   (United States)

^c EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; BRAIN; DISEASES; PROTEINS;

ALZHEIMER'S DISEASE; NEURODEGENERATIVE DISEASE; PARKINSON'S DISEASE;

NEUROLOGY;

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; FLURBIPROFEN; LEVO FLURBIPROFEN;

AGGREGATION; BRAIN; DISEASE INCIDENCE; NEUROLOGY; PROTEIN;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CLINICAL FEATURE; CLINICAL TRIAL; COURSE EVALUATION; DRUG EFFICACY; DRUG RESEARCH; GENETIC RISK; HUMAN; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT;

EID: 33750361540     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05290     Document Type: Review

References (91)

1. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psychisch. Gerichtl. Med. 64, 146-148 (1907).
2. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
3. Glenner, G. G. & Wong, C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984).
4. Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245-4249 (1985).
5. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
6. Klunk, W. E. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598-10606 (2005).
7. Mathis, C. A., Klunk, W. E., Price, J. C. & DeKosky, S. T. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch. Neurol. 62, 196-200 (2005).
8. Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 59, 512-519 (2006).
9. Dodart, J. C., Mathis, C., Bales, K. R. & Paul, S. M. Does my mouse have Alzheimer's disease? Genes Brain Behav. 1, 142-155 (2002).
10. Fernagut, P. O. & Chesselet, M. F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17, 123-130 (2004).
11. Roses, A. D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-400 (1996).
12. Satoh, J. & Kuroda, Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 189, 113-117 (2001).
13. Jarrett, J. T. & Lansbury, P. T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
14. Ross, C. A. & Poirier, M. A. Opinion: what is the role of protein aggregation in neurodegeneration? Nature Rev. Mol. Cell Biol. 6, 891-898 (2005).
15. Hsiao, K. & Prusiner, S. B. Molecular genetics and transgenic model of Gertsmann-Straussler-Scheinker disease. Alzheimer Dis. Assoc. Disord. 5, 155-162 (1991).
16. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
17. Rosen, A. D. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch. Neurol. 35, 638-642 (1978).
18. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991).
19. Lemere, C. A. et al. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16-32 (1996).
20. Dickson, D. W. et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13, 179-189 (1992).
21. Kuo, Y. M. et al. Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276, 12991-12998 (2001).
22. Slow, E. J. et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl Acad. Sci. USA 102, 11402-11407 (2005).
23. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
24. Morgan, D. et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000).
25. Chen, L. & Feany, M. B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nature Neurosci. 8, 657-663 (2005).
26. Bowman, A. B., Yoo, S. Y., Dantuma, N. P. & Zoghbi, H. Y. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum. Mol. Genet. 14, 679-691 (2005).
27. Nagy, Z. et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 165-170 (1997).
28. Roher, A. E. & Kuo, Y. M. Isolation of amyloid deposits from brain. Methods Enzymol. 309, 58-67 (1999).
29. Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125 (1997).
30. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M. & Teplow, D. B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372 (1997).
31. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448-6453 (1998).
32. Hoshi, M. et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl Acad. Sci. USA 100, 6370-6375 (2003).
33. Quist, A. et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl Acad. Sci. USA 102, 10427-10432 (2005).
34. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury, P. T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
35. Lashuel, H. et al. Mixtures of wild-type and "Arctic" Aβ40 in vitro accumulate protofibrils, including amyloid pores. J. Mol. Biol. 332, 795-808 (2003).
36. Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
37. Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M. & Selkoe, D. J. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. (Lond.) 572, 477-492 (2006).
38. Cohen, E., Bieschke, J., Perciavalle, R. M., Kelly, J. W. & Dillin, A. Opposing activities protect against age onset proteotoxicity. Science advance online publication, 10 August 2006 (doi:10.1126/science.1124646).
39. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571-576 (2000).
40. Rochet, J. C., Conway, K. A. & Lansbury, P. T. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein. Biochemistry 39, 10619-10626 (2000).
41. Poirier, M. A. et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277, 41032-41037 (2002).
42. Anguiano, M., Nowak, R. J. & Lansbury, P. T. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41, 11338-11343 (2002).
43. Green, J. D., Goldsbury, C., Kistler, J., Cooper, G. S. & Aebi, U. Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J. Biol. Chem. 279, 12206-12212 (2004).
44. Dobson, C. M. Protein folding and misfolding. Nature 426, 884-890 (2003).
45. Mukai, H. et al. Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc. Natl Acad. Sci. USA 102, 10887-10892 (2005).
46. Lee, H. J. & Lee, S. J. Characterization of cytoplasmic α-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48976-48983 (2002).
47. Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
48. Riesner, D. et al. Disruption of prion rods generates 10-nm spherical particles having high alpha-helical content and lacking scrapie infectivity. J. Virol. 70, 1714-1722 (1996).
49. Silveira, J. R. et al. The most infectious prion protein particles. Nature 437, 257-261 (2005).
50. Roher, A. E. et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20631-20635 (1996).
51. Pountney, D. L. et al. Annular α-synuclein species from purified multiple system atrophy inclusions. J. Neurochem. 90, 502-512 (2004).
52. Lashuel, H. A. & Lansbury, P. T. J. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. advance online publication 18 September 2006 (doi:10.1017/50033583506004422).
53. Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
54. Chartier-Harlin, M. C. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 (2004).
55. Maraganore, D. M. et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. J. Am. Med. Assoc. 296, 661-670 (2006).
56. Nilsberth, C. et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nature Neurosci. 4, 887-893 (2001).
57. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nature Med. 4, 1318-1320 (1998).
58. El-Agnaf, O. M. et al. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440, 71-75 (1998).
59. Greenbaum, E. A. et al. The E46K mutation in α-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800-7807 (2005).
60. Hart, P. J. Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr. Opin. Chem. Biol. 10, 131-138 (2006).
61. Sato, T. et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology 65, 1954-1957 (2005).
62. Perutz, M. F. & Windle, A. H. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412, 143-144 (2001).
63. Gusella, J. F. & MacDonald, M. E. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nature Rev. Neurosci. 1, 109-115 (2000).
64. Lansbury, P. T. Structural neurology: are seeds at the root of neuronal degeneration? Neuron 19, 1151-1154 (1997).
65. Mayeux, R. et al. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46, 412-416 (1999).
66. Cupers, P. et al. The discrepancy between presenilin subcellular localization and γ-secretase processing of amyloid precursor protein. J. Cell Biol. 154, 731-740 (2001).
67. Parchi, P. et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 39, 767-778 (1996).
68. Hand, C. K. et al. Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Ann. Neurol. 49, 267-271 (2001).
69. Restagno, G. et al. The IVS1 +319 t>a of SOD1 gene is not an ALS causing mutation. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6, 45-49 (2005).
70. Hasegawa, K., Yamaguchi, I., Omata, S., Gejyo, F. & Naiki, H. Interaction between A β(1-42) and A β(1-40) in Alzheimer's β-amyloid fibril formation in vitro. Biochemistry 38, 15514-15521 (1999).
71. Isaacs, A. M., Senn, D. B., Yuan, M., Shine, J. P. & Yankner, B. A. Acceleration of amyloid β-peptide aggregation by physiological concentrations of calcium. J. Biol. Chem. advance online publication 26 July 2006 (doi:10.1074/jbc.M602061200).
72. Yu, W. et al. Oligomerization of amyloid β-protein occurs during the isolation of lipid rafts. J. Neurosci. Res. 80, 114-119 (2005).
73. Bitan, G., Fradinger, E. A., Spring, S. M. & Teplow, D. B. Neurotoxic protein oligomers - what you see is not always what you get. Amyloid 12, 88-95 (2005).
74. Hartley, D. M. et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884 (1999).
75. White, J. A., Manelli, A. M., Holmberg, K. H., Van Eldik, L. J. & Ladu, M. J. Differential effects of oligomeric and fibrillar amyloid-β 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18, 459-465 (2005).
76. Cleary, J. P. et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nature Neurosci. 8, 79-84 (2005).
77. Lindersson, E. et al. Proteasomal inhibition by α-synuclein filaments and oligomers. J. Biol. Chem. 279, 12924-12934 (2004).
78. Gosavi, N., Lee, H. J., Lee, J. S., Patel, S. & Lee, S. J. Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277, 48984-48992 (2002).
79. Komatsu, M. et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880-884 (2006).
80. Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885-889 (2006).
81. Kruger, R. et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 56, 1355-1362 (2001).
82. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
83. Janus, C. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982 (2000).
84. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916-919 (2000).
85. DeMattos, R. B. et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850-8855 (2001).
86. Gervais, F. et al. Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging (in the press) published online 3 May 2006 (doi:10.1016/j.neurobiolaging.2006.02.015).
87. McGeer, P. L., Schulzer, M. & McGeer, E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432 (1996).
88. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
89. Morihara, T., Chu, T., Ubeda, O., Beech, W. & Cole, G. M. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J. Neurochem. 83, 1009-1012 (2002).
90. Eriksen, J. L. et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ 42 in vivo. J. Clin. Invest. 112, 440-449 (2003).
91. Kopito, R. R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524-530 (2000).